Citi has increased its target price for AstraZeneca to £186 from £178, maintaining a 'buy' rating after positive clinical developments, especially for the drug tozorakimab. The broker raised peak sales forecasts for tozorakimab to $7 billion and SERENA-6 to $1.1 billion, offsetting the removal of SERENA-4 forecasts. Despite a 15% share price drop this year, Citi remains optimistic due to promising phase 3 trial results and upcoming catalysts like the AVANZAR trial and HICKORY data release. The new target price suggests further upside potential for AstraZeneca shares.
AstraZeneca shares are trading at USD 160.35 on Pluang as of Oct 06, 2026 20:11 WIB, showing a 1-day gain of 2.44%. The stock's market cap stands at $241.60 billion, reflecting significant investor interest. Despite the recent positive clinical news, typical hold time for AstraZeneca on Pluang is 126 days, indicating a moderately long-term investment horizon.
